These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 38167329)

  • 41. New CARs on and off the road: challenges and new developments in CAR-T cell therapy.
    Wehrli M; Maus MV
    Curr Opin Pharmacol; 2021 Aug; 59():116-126. PubMed ID: 34198161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthetic immunity by remote control.
    Gamboa L; Zamat AH; Kwong GA
    Theranostics; 2020; 10(8):3652-3667. PubMed ID: 32206114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chimeric antigen receptors that trigger phagocytosis.
    Morrissey MA; Williamson AP; Steinbach AM; Roberts EW; Kern N; Headley MB; Vale RD
    Elife; 2018 Jun; 7():. PubMed ID: 29862966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands.
    Chang ZL; Hou AJ; Chen YY
    Nat Protoc; 2020 Apr; 15(4):1507-1524. PubMed ID: 32103205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intelligent cell-based therapies for cancer and autoimmune disorders.
    Chen R; Jing J; Siwko S; Huang Y; Zhou Y
    Curr Opin Biotechnol; 2020 Dec; 66():207-216. PubMed ID: 32956902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety.
    Halim L; Ajina A; Maher J
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):117-125. PubMed ID: 29909912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
    Qian L; Chen J; Wu X; Jing R; Sun J
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAR T cells: Building on the CD19 paradigm.
    Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
    Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthetic therapeutic gene circuits in mammalian cells.
    Ye H; Fussenegger M
    FEBS Lett; 2014 Aug; 588(15):2537-44. PubMed ID: 24844435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomaterials for chimeric antigen receptor T cell engineering.
    Niu H; Zhao P; Sun W
    Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthetic Notch-Receptor-Mediated Transmission of a Transient Signal into Permanent Information via CRISPR/Cas9-Based Genome Editing.
    Sgodda M; Alfken S; Schambach A; Eggenschwiler R; Fidzinski P; Hummel M; Cantz T
    Cells; 2020 Aug; 9(9):. PubMed ID: 32825374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
    Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
    Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
    Huang D; Miller M; Ashok B; Jain S; Peppas NA
    Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.
    Morsut L; Roybal KT; Xiong X; Gordley RM; Coyle SM; Thomson M; Lim WA
    Cell; 2016 Feb; 164(4):780-91. PubMed ID: 26830878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in modular control of CAR-T therapy with adapter-mediated CARs.
    McCue AC; Yao Z; Kuhlman B
    Adv Drug Deliv Rev; 2022 Aug; 187():114358. PubMed ID: 35618140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.